Given the increase in complexity of the drug discovery process, the overall R&D spending in the pharmaceutical contract manufacturing / biotechnology sector has grown from around USD 128 billion in 2008 to USD 158 billion in 2017. As a result, the industry is currently under tremendous pressure not only to meet the expectations of a